Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 All time
- Disclosed funding
- $19.1B 398 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| ST SiccaNova TherapeuticsCompany profile A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. | ¥1.3B | Series A | Biotech | Japan | Investors | |
| TT Typewriter TherapeuticsCompany profile Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. | $56M | Series A | Biotech | United States | Investors | |
 DorothCompany profile Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. | $4.5M | Funding roundUndisclosed | Biotech, Agritech | Brazil | Investors | |
| D DataHowCompany profile DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. | Undisclosed | Bridge financingUndisclosed | Biotech, Enterprise software | Switzerland | Investors | |
| NT NovaGo TherapeuticsCompany profile NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. | CHF 24M | Series B | Biotech | Switzerland | Investors | |
| AT Amyl TherapeuticsCompany profile Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. | €8.3M | Series A extensionSeries A | Biotech | Belgium | Investors | |
| IT IntraGel Therapeutics, Ltd.Company profile IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration. IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration. | $7M | Strategic investmentUndisclosed | Biotech | Israel | Investors | |
| S SenticellCompany profile Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells. Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells. | $7M | Seed | Biotech | United States | Investors | |
| PT PANDA TherapeuticsCompany profile PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. | CHF 100K | Venture Kick Stage IIIUndisclosed | Biotech | Switzerland | Investors | |
| A Develops oligonucleotide therapeutics targeting chronic hepatitis B | $120M | Series CSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.